Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

The US regulator cleared the IL-31 inhibitor as a pre-filled pen for subcutaneous injection ... Regeneron's big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), which became the first ...

The green light for the pre-filled, single-use pen version of Tezspire (tezepelumab ... such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra ...

Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application ... the successful launch of Dupixent for chronic obstructive ...